At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 96 enrolled
Drug / intervention
K-877-ER (Dose A) +2 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Multicenter, Randomized, Open-Label, 4-Week Study to Investigate the Efficacy and Pharmacokinetic Profile of K-877-ER Once Daily Treatment Compared to K-877-IR Twice Daily Treatment in Adult Patients With Fasting Triglyceride Levels
In Brief
A Phase 2 clinical trial evaluating K-877-ER (Dose A), K-877-ER (Dose B), and 1 other intervention for Dyslipidemia. Completed, enrolled 96 participants across 12 sites.
Detailed Summary
A study to evaluate the efficacy of K-877 extended release (ER) once daily (QD) compared to K-877 immediate release (IR) twice daily (BID).
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsDyslipidemia
CountriesUnited States
Collaborators--
Timeline
Phase 2CompletedFinished
202120222023202420252026
Enrollment StartJun 2020
First PostedJun 2020
Primary CompletionDec 2020
TodayJul 2026
First PostedJun 25, 2020
Enrollment StartJun 10, 2020
Primary CompletionDec 3, 2020
TodayJul 2, 2026
Enrollment to primary: 6 monthsPosted 6.0 years ago
Interventions
K-877-ER (Dose A)drug
Dose A Oral Administration
K-877-ER (Dose B)drug
Dose B Oral Administration
K-877-IRdrug
K-877-IR Oral Administration